Compare Eli Lilly And Co (LLY) vs Orion Office REIT Inc (ONL) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

ONL trades at $2.65, up 0.76% today, with a bullish technical signal despite bearish moving averages. The company reported Q1 2026 earnings with a net loss of $0.24 per share, missing estimates, while revenue declined to $147.65 million in 2025. A strategic review is underway with Wells Fargo and JPMorgan, focusing on portfolio repositioning and debt management, as highlighted in recent earnings calls (MarketBeat, 2026-05-14).

Outlook remains challenging due to persistent losses and high leverage, but the strategic shift toward dedicated-use assets and resolved refinancing risks offer potential upside. Investors face significant execution and market headwinds, with analyst consensus split evenly between Buy and Hold ratings.